Objective: Despite viral suppression and immune response on antiretroviral therapy, people with HIV infection experience excess mortality compared with uninfected individuals. The Veterans Aging Cohort Study (VACS) Index incorporates clinical biomarkers of general health with age, CD4 þ cell count, and HIV-1 RNA to discriminate mortality risk in a variety of HIV-positive populations. We asked whether additional biomarkers further enhance discrimination.
Introduction
With antiretroviral treatment (ART), people with HIV infection (PWH) typically achieve viral suppression, leading to increasing CD4 þ cell count. However, their health remains compromised compared with demographically similar individuals without HIV [1] [2] [3] [4] . Traditional HIV biomarkers (CD4 þ cell count and HIV-1 RNA) are no longer sufficient for clinical management and research. The Veterans Aging Cohort Study (VACS) Index, a validated, generalizable risk index [5] , employs routine clinical data to provide a summary of overall disease burden. Higher scores indicate increasing risk of all-cause mortality, hospitalization [6] , medical intensive care admission [6] , cardiovascular disease [7] , fragility fractures [8] , and cognitive compromise [9, 10] . The original Index (version 1.0) includes age, CD4
þ , HIV-1 RNA, and general health biomarkers [hemoglobin (Hb), alanine and aspartate (AST) transaminases, platelets, creatinine, and hepatitis C virus (HCV) serostatus]. Adding these biomarkers to an index restricted to age, CD4 þ and HIV-1 RNA substantially improved discrimination (c-statistic: 0.78 vs. 0.72) [5] .
Although widely used, VACS Index 1.0 has limitations. It categorizes predictors to simplify calculation and interpretation, limiting its ability to detect small changes. Although discrimination (how well those who die are distinguished from those who do not) is better than other risk indices in common use [11] [12] [13] [14] adding predictors might further improve discrimination. Blood pressure, cholesterol, and smoking did not improve VACS Index 1.0 [15] , but team clinicians suggested other variables shown to be associated with poor outcomes. These include nadir CD4 þ , CD8 þ , CD4 þ : CD8 þ ratio [16, 17] , albumin [18] [19] [20] [21] , white blood count (WBC) or absolute neutrophil count (ANC) [22, 23] , and BMI [24, 25] .
We aimed to develop an improved VACS Index (2.0), externally validate using data from European and North American cohorts participating in the Antiretroviral Therapy Cohort Collaboration (ART-CC), and evaluate generalizability among important subgroups.
Methods
Development of Veterans Aging Cohort Study Index 2.0 We developed VACS Index 2.0 using patients from VACS, a cohort of all HIV-infected US military veterans in Veterans Health Administration care [26] . For this analysis, eligible patients were at least 18 years old, initiated ART between 1996 and 2014, and had a visit between 2000 and 2014. We excluded 2782 individuals who had negative HCV RNA (at any time during the study period) after previously having detectable HCV RNA, because they may have received treatment for HCV infection or spontaneously cleared the virus. Few patients were treated for HCV prior to availability of direct acting antivirals (DAA) starting in 2014 and there is not yet long-term follow-up for those treated with DAAs. We obtained all laboratory values and BMI for a given individual for each visit date, at least 1 year after ART initiation. Values obtained prior to the visit date were allowed to carry forward for up to 180 days, resulting in complete information for 75% of visits. In sensitivity analysis, allowing values to carry forward for 1 year, 87% of visits had complete data. We randomly selected a visit date for each patient from among those with complete data to represent a typical patient in care. In addition to outpatient data, laboratory results obtained during hospitalization were included to provide a wider range of values. We only included one random day per hospitalization in the visit pool to avoid over-representation in the sampled visit days. Patients were followed up to 5 years for all-cause mortality until 30 September 2016. Ascertainment of deaths of Veterans Health Administration patients is excellent [27, 28] .
We first replicated the previously published VACS Index (1.0) by fitting a Cox model in the newly derived dataset using categorical predictors (age, CD4
þ cell count, HIV-1 RNA and laboratory measurements of Hb, AST and alanine transaminases, platelets, creatinine, and HCV status). Composite markers of liver and renal injury were calculated. FIB-4 is a validated indicator of liver fibrosis [29] . Estimated glomerular filtration rate (eGFR) is a validated indicator of impaired renal function based on the Chronic Kidney Disease Epidemiology Collaboration equation [30] . HCV infection status was based on detectable plasma HCV-RNA (85%), positive antibody test (10%), or documented diagnosis (5%). Once testing HCV positive, patients were assumed to remain positive (since we excluded treated patients). For comparison, we also modeled VACS Index 1.0 predictors as continuous variables, as described below.
We then evaluated additional candidate variables, one at a time and in combination, using Akaike's information criterion (lower is better) for model fit and Harrell's cstatistic (range 0.5-1.0, higher is better) for discrimination. We used categorical variables with 10 levels for each predictor, with equal number of deaths in each category. We fitted Cox models and plotted coefficients of categorized variables by median of each category. Categories were refined to assess shape of the curve, maintaining at least 100 deaths per level. We determined an appropriate continuous functional form for each variable including quadratic, cubic, and natural log terms to account for U-shaped associations. Extreme values were replaced with the 1st or 99th percentile to avoid undue influence; most variables were centered at the median. Splines were used if a suitable polynomial form was not found. Once a candidate final model was developed, we left out one variable at a time to see if any predictor could be dropped without affecting model fit and discrimination.
To create scores, we used regression coefficients, estimated in this sample, for VACS Index 1.0 (original index, categorical variables) and VACS Index 2.0 (additional predictors, continuous variables). We applied regression equations to each patient using their lab values and the model coefficients to create linear predictors for each index, which were then scaled to create scores of approximately 0-100. To illustrate in a clinically meaningful way, we calculated scores using a range of plausible values (between lowest and highest included in the model) for each predictor, while setting all others to the median. The range of scores showed which predictors had the greatest influence.
Validation of Veterans Aging Cohort Study Index 2.0 We validated VACS Index 2.0 using data from ART-CC (described elsewhere [31] ), an international collaboration combining data on PWH from Europe and North America. Eligible cohorts contributed data on laboratory values of interest and reported at least 40 deaths in such patients. Included cohorts were randomly assigned a letter from A through I for anonymity. Patients and laboratory values were selected using the same approach as described for VACS patients, but without any limitation of values obtained during hospitalization (hospitalization dates were not available). The proportion of visit dates with complete information varied between 5 and 82% by cohort. Those with linkage to an electronic health record (EHR) had more complete data. In sensitivity analysis we compared discrimination between cohorts with at least 50% completeness to those with less than 50%.
Using VACS Index scores as predictors we compared performance in VACS and ART-CC (overall and by cohort). We evaluated discrimination using c-statistics, hazard ratios per 5-U increase in VACS Index 2.0 score in Cox models, and Kaplan-Meier plots by decile of risk (customized for VACS and ART-CC to have equal number of deaths per decile). We evaluated discrimination at varying lengths of follow-up (30, 90 days, 6 months, 1, 2, 3, 4, and 5 years) using fixed weights from 5-year outcome models developed in VACS.
Performance across subgroups
Finally, development and validation datasets were combined to evaluate performance in subgroups [women; those with HIV-1 RNA < 500 copies/ml; HCV coinfected patients; and low-risk patients (age <50 years, CD4 þ cell count !200 cells/ml, and HIV-1 RNA 500 copies/ml)]. Those not meeting criteria for low risk were categorized as high risk. We calculated cstatistics and mortality rates in patients defined as low risk and high risk as a function of VACS Index 2.0 score.
We used SAS version 9.4 (SAS Institute, Cary, North Carolina, USA) for all analyses, except that calculation of Harrell's c-statistic used Stata version 14 (Stata Corp., College Station, Texas, USA). Institutional review boards from each cohort approved analysis of routinely collected data.
Results
Half the randomly selected visit dates were in 2010 and later (Table 1 ). Among 28 390 VACS patients there were 7293 deaths (7.2 per 100 person-years); 39% occurred in the first year of follow-up. Median time on ART at the random visit date was 4.2 years; subsequent median follow-up was 4.1 years. Among 12 109 ART-CC patients, there were 722 deaths (2.0 per 100 personyears, ranging 1.2-4.5 by cohort); 44% occurred in the first year. Median time on ART was 4.2 years, median follow-up was 3.2 years. Compared with ART-CC, VACS patients were older (median 53 vs. 43 years), more likely to be male (98 vs. 74%) and more likely to have initiated ART before 1999 (Table 1) . VACS patients were less likely than ART-CC patients to be virally suppressed (76 vs. 88%) or defined as low risk (24 vs. 60%). (24) 7303 (60) ART, antiretroviral therapy; ART-CC, Antiretroviral Therapy Cohort Collaboration; eGFR, estimated glomerular filtration rate; FIB-4, (years of age Â AST)/(platelets in 10
In VACS (development) data, model fit and discrimination improved with addition of CD4 þ : CD8 þ ratio, BMI, albumin, and WBC, individually and in combination, compared with VACS Index 1.0 (Appendix Fig. 1 Polynomial forms were found for all variables except eGFR which was modeled using splines (Appendix Table 1 , http://links.lww.com/QAD/B426). Extending last value carried forward time to 1 year provided less than 3% additional visit dates or deaths, and all estimates were similar to those obtained using 180 days in the main analysis.
When scores were calculated across a plausible range: age and albumin had the greatest influence. To illustrate, age 30 corresponds to 32 points and age 75 corresponds to 59 points, for a range of 27 points. An albumin of 2.0 g/dl corresponds to 65 points and 5.0 g/dl corresponds to 39 points, for a range of 26 points (Appendix Table 2 (Fig. 1a) . In cohorts with at least 50% completeness in the visit pool and in those with less than 50% completeness, the c-statistic was greater with VACS Index 2.0, with no separation in CIs comparing completeness. At all followup intervals VACS Index 2.0 had greater discrimination than 1.0 (Fig. 1b and c) . As expected, c-statistics were greater for shorter follow-up. In addition, improvement from VACS Index 1.0-2.0 was greatest for shorter follow-up.
Kaplan-Meier plots by decile of risk (Fig. 2 , Appendix Table 4 , http://links.lww.com/QAD/B426) in VACS showed better separation with VACS Index 2.0 compared with 1.0. Although VACS Index 1.0 deciles 6 and 7 overlapped until 1 year, VACS Index 2.0 deciles were all distinct around 6 months of follow-up. Survival at 5 years for extreme deciles expanded from 13 to 92% with VACS Index 1.0 to 8-93% with VACS Index 2.0. In ART-CC, with only one-tenth as many deaths, curves were less distinct, but also showed improvement with VACS Index 2.0. The range of 5-year survival expanded from 35 to 97% with VACS Index 1.0 to 25-98% with 2.0. Similar patterns were seen with 1-year survival. In both VACS and ART-CC median survival was less than a year for those in the highest VACS Index 2.0 decile. Based on above findings we combined VACS and ART-CC data to look at subgroups.
Combined data demonstrated higher c-statistics for VACS Index 2.0 than 1.0 for all subgroups ( Mortality rates in both low-risk and high-risk patients had strong and similar associations with VACS Index 2.0 score (Fig. 4) .
Discussion
VACS Index 2.0 had better discrimination than 1.0 in development (VACS) and external validation (ART-CC) data. This was achieved by study design; treating all predictors as continuous; and adding albumin, WBC, and BMI. Improved discrimination was evident across a variety of important subgroups, varying length of followup and across ART-CC cohorts. Improved discrimination was evident beyond c-statistics. Compared with VACS Index 1.0, Kaplan-Meier plots comparing deciles of 2.0 showed better separation of mortality risk during the first 6-12 months of follow-up that persisted across the 5-year follow-up. In both low-risk and high-risk patients there was a strong and consistent gradient of higher mortality with increasing score. Improved discrimination of VACS Index 2.0 was shown to be transportable to other settings [32] . Thus, VACS Index 2.0 can be used as a measure of disease burden for risk adjustment and/or as an outcome for clinical research. With automated calculation and risk interpretation by way of smartphone apps, online calculators, or decision support modules in EHRs, it can also be incorporated in medical decision making.
Generalizability of VACS Index 2.0 was likely enhanced by our study design. Because we started follow-up from a randomly selected date, the index was designed around a typical patient in care, rather than optimizing for some fixed point in clinical management. Including laboratory values obtained during hospitalization increased the range of severity of illness represented in model development data. VACS Index 2.0 predictors are continuous, offering important advantages over the thresholds in VACS Index 1.0. For example, on the day a patient turns 50 the VACS Index 1.0 score increases by 12 points, translating to roughly 40% increased risk of mortality. Although this risk is accurate in aggregate for those aged 50-64 years, no individual would experience such an abrupt change. VACS Index 2.0 models this change in risk smoothly across ages. Thresholds in VACS Index 1.0 limited investigator's ability to use the index as an outcome to detect change from baseline to end of observation. With continuous variables more subtle changes in risk can be detected, enhancing suitability for longitudinal patient management.
Addition of albumin, WBC, and BMI enhanced discrimination of the index, and provided interesting insights. After age, albumin is the single most important marker of general health in the model. Low serum albumin may be associated with multiple HIV-related conditions (e.g. poor nutritional status, inflammation, nephropathy, and liver disease). We suspect that albumin is particularly important as an added indication of liver disease, which is increasingly common among those aging with HIV. In VACS Index 1.0 liver injury was only ascertained with FIB-4 and an indicator for HCV infection. Albumin measures liver synthetic function, thus enhancing detection of injury. We chose not to include hospitalization as a predictor because we want to use the index to predict future hospitalization. In addition, hospitalization can be considered a downstream event in the causal pathway between VACS Index components and death. Inclusion would obfuscate associations with validated predictors. Finally, varying reasons for hospitalization have different associations with mortality. VACS Index 2.0 is a stronger predictor than 1.0. Despite having similar ranges of scores, the hazard ratio for 5 years, all-cause mortality increased from 1.221 (1.216-1.227) per 5 points with VACS Index 1.0, to 1.307 (1.300-1.314) per 5 points with VACS Index 2.0. VACS Index 2.0 is better able to identify high-risk patients within 6 months of follow-up. In the 10th decile on KaplanMeier plots, estimated 6-month survival in VACS patients decreased from 61% with VACS Index 1.0 to 51% with VACS Index 2.0. In ART-CC this change was 74-59%.
Significantly, VACS Index 2.0 had higher discrimination in validation (ART-CC) than in development (VACS). This was also observed in validation of VACS Index 1.0 in ART-CC [5] . There are several possible explanations. First, follow-up time in ART-CC was shorter. All else equal, proximal deaths are easier to predict than distant deaths. Second, ART-CC subjects are younger and discrimination is slightly better among those under 50 years. Finally, the index is not designed to detect risk of unnatural deaths, such as suicide, accident, or overdose. Such deaths are more common in veteran populations [33, 34] .
In prognostic modeling, important subgroups may be underrepresented, such as women in VACS. Therefore, it is important to demonstrate discrimination within these groups. We found superior discrimination with VACS Index 2.0 in all subgroups (including women) and among each of the nine participating cohorts in ART-CC. These observations offer strong evidence that improved discrimination of VACS Index 2.0 will generalize to new populations. It also suggests that the strong associations previously demonstrated with VACS Index 1.0 and biomarkers of inflammation [16, [35] [36] [37] , hospitalization and medical ICU admission [38] , myocardial infarction [7] , neurocognitive performance [9, 10] , and fragility fractures [8, 39] will hold for 2.0.
Of note, improvement in discrimination from VACS Index 1.0 to 2.0 was unusually large in cohort F, increasing from 0.790 (95% CI 0.744, 0.835) to 0.873 (0.841, 0.906). We think this is due to missing data leading to selection of sicker patients with higher short-term mortality. Only 5% of visits had complete data. According to cohort personnel, selecting people with both Hb and albumin likely sampled some of the sickest subjects, likely to die over a short interval of time. In fact, 40% of deaths occurred in the first 6 months, 10% higher (absolute) than any other cohort. Increased discrimination from VACS Index 1.0 to 2.0 was greatest for shorter follow-up times (Fig. 1c) .
The original VACS Index has been increasingly used in a variety of research, public health, and clinical settings. Since March 2013, online calculators (https://vacs.med.yale.edu; https://www.mdcalc.com/veterans-agingcohort-study-vacs-index) have been accessed more than 80 000 times. The index has been used as a risk adjuster in observational studies [25, 40] . Two ongoing NIH funded, alcohol intervention trials and the AIDS Clinical Trials Group use the VACS Index in randomized trials [41] . Independent groups are using the index as a measure of frailty or severity of illness [10, 36, 37, [42] [43] [44] [45] [46] [47] [48] [49] [50] . In addition, the index is being used in surveillance. The Public Health-Seattle & King County, HIV/STD Program and the Washington State Department of Health use the index to monitor burden of disease among PWH. Several health systems have incorporated the index as a tool within their EHR for patient management. VACS Index 2.0 will enhance utility for all these applications.
An important limitation of VACS Index 2.0 is that we have not incorporated prognostic implications of HCV cure. Although patients treated for HCV were excluded from development sample, and most follow-up in validation sample is before widespread availability of DAAs, treatment of HCV may still have influenced our findings. In future work we hope to address this limitation once adequate mortality data are available among PWH treated for HCV coinfection. Another limitation is that we could only consider nadir CD4 þ as observed within the Veterans Health Administration EHR, without being sure it is truly the lowest prior to ART initiation missing data may also be a concern. We only randomly selected visit dates when patients had complete data within the prior 180 days. Nonetheless we found consistent results across all cohorts regardless of the proportion of visits with complete data. Finally, we have yet to conduct analyses determining calibration of VACS Index 2.0. As with the original index, we plan to conduct this analysis in an even broader array of cohorts in the coming months.
In conclusion, VACS Index 2.0 is highly predictive of risk of all-cause mortality among those on treatment for HIV infection. With use of continuous variables, it is now better suited to application for individual patients. With addition of parameters readily obtained during routine clinical practice it is more discriminating than the original VACS Index. Its superior discrimination is robust across development and validation sets, among important clinical subgroups, and among individual cohorts.
